Fertility and Sterility
Volume 88, Issue 4 , Pages 779-780, October 2007

Limiting access to letrozole—is it justified?

  • Togas Tulandi, M.D., M.H.C.M.

      Affiliations

    • Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Togas Tulandi, M.D., M.H.C.M., Department of Obstetrics and Gynecology, McGill University, Women's Pavilion, 687 Pine Avenue West, Montreal, H3A 1A1, Quebec, Canada (FAX: 514-843-1448).
    • ,
  • Alan H. DeCherney, M.D.

      Affiliations

    • Reproductive Biology and Medicine Branch, National Institute of Health and Development, Bethesda, Maryland

Received 15 November 2006; received in revised form 22 January 2007; accepted 22 January 2007. published online 25 April 2007.

Letrozole is an effective drug for ovulation induction and superovulation. Limiting its access is a disservice to our infertile patients and to the advancement in ovulation-related research.

Key Words: Letrozole, aromatase inhibitor, congenital malformation, teratogenicity, ovulation induction, ovulation, research

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0015-0282(07)00275-0

doi:10.1016/j.fertnstert.2007.01.115

Fertility and Sterility
Volume 88, Issue 4 , Pages 779-780, October 2007

Article Tools